Chitosan-decorated selenium nanoparticles as protein carriers to improve the in vivo half-life of the peptide therapeutic BAY 55-9837 for type 2 diabetes mellitus.

Int J Nanomedicine · 2014 · PMC4207575 · PMID 25378923

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

13 The in vivo half-life of protein-based products significantly affects both dosing requirements and therapeutic efficacy; therefore, strategies to prolong the half-life of such drugs are highly significant.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.